Expert View on the Evolving Treatment Paradigm in Advanced NSCLC
  • CME
  • CE

Review expert insights on the latest clinical data informing optimal management of patients with advanced NSCLC using targeted agents and immune checkpoint inhibitors.
Matthew Gubens, MD, MS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: June 23, 2020 Expiration: June 22, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess the appropriate molecular markers to guide clinical decisions for patients with advanced-stage NSCLC
  • Integrate into practice the available clinical evidence and expert recommendations after definitive platinum-based chemotherapy and concurrent radiation therapy
  • Plan individualized treatment strategies for patients with advanced NSCLC positive for actionable genetic aberrations, or high PD-L1 expression, taking into consideration the available data and consensus expert recommendations
  • Plan treatment strategies using immune checkpoint inhibitors as first-line treatment options for patients with advanced NSCLC
  • Describe the role of combination approaches to optimize immune checkpoint inhibitor efficacy and reduce treatment resistance
  • Appropriately manage treatment-related adverse events associated with targeted and immune checkpoint inhibitor treatment options used in patients with NSCLC


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Produced in collaboration with
Grace Logo
Supported by educational grants from
Bristol-Myers Squibb
Celgene Corporation
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, BeyondSpring, Boehringer Ingelheim, Bristol-Myers Squibb, Inivata, and Takeda and funds for research support (to his institution) from Celgene, Merck, Novartis, OncoMed, and Roche.


Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Bing-e Xu, PhD

Scientific Director

Bing-E Xu, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Elaine S. DeMeyer, MSN, RN, AOCN

Editorial Contributor

Elaine DeMeyer, RN, MSN, AOCN, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with non-small-cell lung cancer.


The goal of this activity is to improve learners’ competence in applying the latest practice-changing data in the individualized clinical management of patients with locally advanced or metastatic non-small-cell lung cancer.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-068-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 23, 2020, through June 22, 2021:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

In this slideset from Clinical Care Options, Jamie E. Chaft, MD and Kristin Higgins, MD review the role of IO therapy and CRT for early stage NSCLC.

Jamie E. Chaft, MD Kristin Higgins, MD Released: October 23, 2020

Gain key clinical insights fast, with this short slideset from CCO on new biomarkers driving precision care in lung cancer

Edward S. Kim, MD, FACP Sandip P. Patel, MD Released: October 23, 2020

In this slideset from Clinical Care Options, Jamie E. Chaft, MD and Kristin Higgins, MD provides insights on the latest data on IO therapy for lung cancer.

Jamie E. Chaft, MD Kristin Higgins, MD Released: October 23, 2020

Downloadable slideset with key data from the 2020 ESMO Virtual Congress created by Clinical Care Options (CCO)

Yelena Y. Janjigian, MD Joyce O'Shaughnessy, MD Elizabeth R. Plimack, MD, MS person default Vamsidhar Velcheti, MD Released: October 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.